Browsing by Author Spencer, Andrew

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2018Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyTrotman, Judith; Balasubramanian, Sriram; Caballero, Dolores; Cheson, Bruce D; Damle, Rajendra; Deshpande, Sanjay; Fowler, Nathan; Gartenberg, Gary; Gopal, Ajay; Hess, Georg; Hou, Jing-Zhou; Jurczak, Wojciech; Lill, Michael; Martin, Peter; Morton, James; Radford, John; Salles, Gilles; Schaffer, Michael; Schuster, Stephen; Spencer, Andrew; Vermeulen, Jessica; Vitolo, Umberto; Wang, Shean-Sheng; Yacoub, Abdulraheem; Concord Clinical School: MedicineIbrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study, Journal of Clinical Oncology, vol.36, 23, 2018,pp 2405-2412
2015Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemiaStevenson, William; Avery, S; Fleming, Shaun; Govindaraj, Chindu; Macmanus, Julie; Patil, S; Perruzza, Sarah; Plebanski, Magdalena; Spencer, Andrew; Tan, Peter; Wei, Andrew; Northern Clinical School: MedicineMaintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia, British Journal of Haematology, vol.169, 2, 2015,pp 199-210
2017Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHo, Joy Phoebe; Bhutani, Divaya; Gyger, M; Inamdar, S; Morris, C; Ou, Y; Quach, Hang; Spencer, Andrew; White, D; White, M; Central Clinical School: MedicinePharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study, Cancer Chemotherapy and Pharmacology, vol.79, 6, 2017,pp 1067-1076
2009Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.Joshua, Douglas; Aklilu, Esther; Brown, R. D.; Gibson, J; Ho, Joy; Kabani, Karieshma; Kennedy, Nola; Spencer, Andrew; Sze, Daniel M.; Yang, Shihong; Central Clinical School: MedicinePrognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma., Leukemia and Lymphoma, vol.50, 11,pp 1860-1864
2005Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.Gibson, John; Prosser, Ian; Bashford, J; et, al; Grigg, Andrew P.; Herrmann, R; Horvath, N; Joske, D; Lowenthal, R; McKendrick, J; Prince, Roger C; Spencer, Andrew; Central Clinical School: Medicine; MedicineProspective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation., Bone Marrow Transplantation, vol.35,(10),2005,pp 971-7
2001Response to erythropoietin in chronic myelomonocytic leukaemiaKerridge, Ian; Azzi, A.; Seldon, M.; Spencer, Andrew; Central Clinical School: Ctr for Values Ethics & Law in MedResponse to erythropoietin in chronic myelomonocytic leukaemia, Internal Medicine Journal, vol.31,(6),2001,pp 371-372
2012Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialBrown, Ross; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Daniher, Daniel; Jeffels, Melinda; Spencer, Andrew; Pharmacy; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial, Leukemia and Lymphoma, vol.53, 9, 2012,pp 1728-1734
2015Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory GroupGibson, John; Ho, Joy Phoebe; Joshua, Douglas; et al, Various; Harrison, Simon James; Horvath, Noemi; Mollee, Peter N; Quach, Hang; Roberts, Andrew; Spencer, Andrew; Szer, Jeff; Talaulikar, Dipti; To, B; Zannettino, Andrew C W; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineTreatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.45, 3, 2015,pp 335-343
2017Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupGibson, John; Ho, Joy Phoebe; Joshua, Douglas; Trotman, Judith; Ward, Christopher; et al, Various; Harrison, Simon; Horvath, Noemi; Lee, Cindy; Mollee, Peter N; Quach, Hang; Roberts, Andrew; Spencer, Andrew; Szer, Jeff; Talaulikar, Dipti; Tam, Constantine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Northern Clinical School: Kolling InstituteTreatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.47, 1, 2017,pp 35-49